StockData
Pacira BioSciences, Inc. logo

Pacira BioSciences, Inc. (PCRX) stock

PCRXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 6/3028% above fair value
$36.48+0.00 (0.00%)

Close on Nov 17, 2026Market cap $1.45BP/E 104.2Yield –

Pacira BioSciences r&d expenses

Research and development expenses are spending on new products and technology.

Pacira BioSciences's R&D Expenses for the twelve months ending Jun 30, 2026 was $121.73M, up 26.1% year over year. For fiscal 2025 it was $117.31M, up 43.8% from the year before. Over ten years it grew 15.1% a year on average. The highest annual figure on record is $117.31M in fiscal 2025.

Annual r&d expenses

PeriodPeriod endValueChange
FY2025Dec 31, 2025$117.31M+43.8%
FY2024Dec 31, 2024$81.58M+7.0%
FY2023Dec 31, 2023$76.26M-10.1%
FY2022Dec 31, 2022$84.80M+52.7%
FY2021Dec 31, 2021$55.55M-6.5%
FY2020Dec 31, 2020$59.42M-17.6%
FY2019Dec 31, 2019$72.12M+29.5%
FY2018Dec 31, 2018$55.69M-2.8%
FY2017Dec 31, 2017$57.29M+25.4%
FY2016Dec 31, 2016$45.68M+59.4%
FY2015Dec 31, 2015$28.66M+53.0%
FY2014Dec 31, 2014$18.73M-13.1%
FY2013Dec 31, 2013$21.56M+117.0%
FY2012Dec 31, 2012$9.94M-33.2%
FY2011Dec 31, 2011$14.87M-20.2%
FY2010Dec 31, 2010$18.63M-29.0%
FY2009Dec 31, 2009$26.23M–

Quarterly r&d expenses

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$30.24M+7.2%
Q1 FY2026Mar 31, 2026$28.07M+10.8%
Q4 FY2025Dec 31, 2025$37.45M+56.7%
Q3 FY2025Sep 30, 2025$25.97M+35.9%
Q2 FY2025Jun 30, 2025$28.20M+38.7%
Q1 FY2025Mar 31, 2025$25.34M+39.0%
Q4 FY2024Dec 31, 2024$23.90M+22.8%
Q3 FY2024Sep 30, 2024$19.10M-8.3%
Q2 FY2024Jun 30, 2024$20.34M+8.0%
Q1 FY2024Mar 31, 2024$18.24M+6.4%
Q4 FY2023Dec 31, 2023$19.46M+11.2%
Q3 FY2023Sep 30, 2023$20.83M+7.3%
Q2 FY2023Jun 30, 2023$18.82M-28.4%
Q1 FY2023Mar 31, 2023$17.14M-20.7%
Q4 FY2022Dec 31, 2022$17.51M+12.8%
Q3 FY2022Sep 30, 2022$19.41M+67.6%
Q2 FY2022Jun 30, 2022$26.28M+109.0%
Q1 FY2022Mar 31, 2022$21.61M+36.1%
Q4 FY2021Dec 31, 2021$15.51M+1.2%
Q3 FY2021Sep 30, 2021$11.58M-21.0%
Q2 FY2021Jun 30, 2021$12.57M-7.7%
Q1 FY2021Mar 31, 2021$15.88M+0.4%
Q4 FY2020Dec 31, 2020$15.33M-22.0%
Q3 FY2020Sep 30, 2020$14.65M-27.7%
Q2 FY2020Jun 30, 2020$13.62M-23.6%
Q1 FY2020Mar 31, 2020$15.82M+10.0%
Q4 FY2019Dec 31, 2019$19.65M+38.7%
Q3 FY2019Sep 30, 2019$20.26M+36.0%
Q2 FY2019Jun 30, 2019$17.83M+45.7%
Q1 FY2019Mar 31, 2019$14.38M+0.0%
Q4 FY2018Dec 31, 2018$14.17M+41.3%
Q3 FY2018Sep 30, 2018$14.90M+26.5%
Q2 FY2018Jun 30, 2018$12.24M-35.1%
Q1 FY2018Mar 31, 2018$14.38M-13.6%
Q4 FY2017Dec 31, 2017$10.03M-41.3%
Q3 FY2017Sep 30, 2017$11.78M+20.7%
Q2 FY2017Jun 30, 2017$18.86M–
Q1 FY2017Mar 31, 2017$16.63M–
Q4 FY2016Dec 31, 2016$17.07M–
Q3 FY2016Sep 30, 2016$9.75M–

More Pacira BioSciences figures

See a number that looks wrong?